Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
03 08 2020
Historique:
pubmed: 11 6 2020
medline: 29 6 2021
entrez: 11 6 2020
Statut: ppublish

Résumé

Oral delivery of poorly water-soluble, weakly basic drugs may be problematic based on the drugs' intrinsic properties. Many drugs in this subset have overcome barriers to delivery following successful formulation as amorphous solid dispersions (ASDs). To process drugs as ASDs, multiple commercially relevant technologies have been developed and become well understood. However, ASD-producing technologies like spray drying and KinetiSol produce ASDs with vastly differing particle characteristics. Ultimately, the objective of this study was to assess whether processing an ASD of identical composition utilizing two different ASD-producing technologies (KinetiSol and spray drying) may impact the oral bioavailability of a weakly basic drug. For this study, we selected a weakly basic drug (Boehringer Ingelheim research compound 639667, BI 667) and processed it with an anionic polymer (hypromellose acetate succinate MMP grade (HPMCAS-MMP)) to evaluate whether the processing technology could modulate drug release in acidic and neutral media. Multiple characterization techniques (specific surface area (SSA), particle size distribution (PSD), scanning electron microscopy (SEM)) were utilized to evaluate the surface characteristics and differences in particles produced by KinetiSol and spray drying. Molecular interactions and drug-polymer miscibility of the processed particles were assessed using Fourier transform infrared spectroscopy and solid-state nuclear magnetic resonance, respectively.

Identifiants

pubmed: 32520562
doi: 10.1021/acs.molpharmaceut.0c00108
doi:

Substances chimiques

Drug Carriers 0
Pharmaceutical Preparations 0
Polymers 0
Water 059QF0KO0R

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2789-2808

Auteurs

Scott V Jermain (SV)

College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States.

Michael B Lowinger (MB)

Merck Research Laboratories (MRL), Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.

Daniel J Ellenberger (DJ)

DisperSol Technologies, LLC, 111 West Cooperative Way, Building 2, Suite 200, Georgetown, Texas 78626, United States.

Dave A Miller (DA)

DisperSol Technologies, LLC, 111 West Cooperative Way, Building 2, Suite 200, Georgetown, Texas 78626, United States.

Yongchao Su (Y)

College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States.
Merck Research Laboratories (MRL), Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.

Robert O Williams (RO)

College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH